Literature DB >> 15227134

Hypertrophic obstructive cardiomyopathy: hemodynamic improvement with intravenous verapamil.

S J Roth1, C B Porter, L A Latson.   

Abstract

We report the reduction in left ventricular outflow tract gradient following the intravenous administration of verapamil to two pediatric patients with hypertrophic obstructive cardiomyopathy. Traditional therapy with beta adrenergic antagonists was relatively contraindicated in both patients. In a 15-year-old patient, the left ventricular outflow tract gradient decreased from 160 torr, at rest, to 45 torr during the verapamil infusion. In a 3-year-old boy, there was a reduction in the left ventricular outflow tract gradient from 60 torr, under basal conditions, to 10 torr during the intravenous verapamil infusion. We believe that verapamil may be effective in reducing the left ventricular outflow tract gradient in some pediatric patients with hypertrophic obstructive cardiomyopathy and may be useful in treating selected patients with this disorder.

Entities:  

Year:  1983        PMID: 15227134      PMCID: PMC341633     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  12 in total

1.  Asymetric septal hypertrophy in childhood.

Authors:  B J Maron; W L Henry; C E Clark; D R Redwood; W C Roberts; S E Epstein
Journal:  Circulation       Date:  1976-01       Impact factor: 29.690

2.  Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status.

Authors:  D R Rosing; K M Kent; B J Maron; S E Epstein
Journal:  Circulation       Date:  1979-12       Impact factor: 29.690

3.  Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration.

Authors:  D R Rosing; J R Condit; B J Maron; K M Kent; M B Leon; R O Bonow; L C Lipson; S E Epstein
Journal:  Am J Cardiol       Date:  1981-09       Impact factor: 2.778

4.  An appreciation of hypertrophic cardiomyopathy.

Authors:  J F Goodwin
Journal:  Am J Med       Date:  1980-06       Impact factor: 4.965

5.  Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects.

Authors:  D R Rosing; K M Kent; J S Borer; S F Seides; B J Maron; S E Epstein
Journal:  Circulation       Date:  1979-12       Impact factor: 29.690

6.  Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy.

Authors:  R O Bonow; D R Rosing; S L Bacharach; M V Green; K M Kent; L C Lipson; B J Maron; M B Leon; S E Epstein
Journal:  Circulation       Date:  1981-10       Impact factor: 29.690

7.  Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy.

Authors:  S E Epstein; D R Rosing
Journal:  Circulation       Date:  1981-09       Impact factor: 29.690

8.  Idiopathic hypertrophic subaortic stenosis in the young.

Authors:  G I Fiddler; A J Tajik; W Weidman; D C McGoon; D G Ritter; E R Giuliani
Journal:  Am J Cardiol       Date:  1978-11       Impact factor: 2.778

9.  Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients.

Authors:  B J Maron; W C Roberts; S E Epstein
Journal:  Circulation       Date:  1982-06       Impact factor: 29.690

10.  Hypertrophic cardiomyopathy in infants: clinical features and natural history.

Authors:  B J Maron; A J Tajik; H D Ruttenberg; T P Graham; G F Atwood; B E Victorica; J T Lie; W C Roberts
Journal:  Circulation       Date:  1982-01       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.